World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
58075
World Ranking
17332
National Ranking
8685

Overview

Edward B. Garon is affiliated with the University of California, Los Angeles in the United States. Their research primarily focuses on the field of Medicine, with specific emphasis on Oncology and Pulmonary and Respiratory Medicine. Other subfields of study include Cancer Research, Molecular Biology, and Immunology.

The scientist has contributed to topics such as:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Immunotherapy and Immune Responses

Their recent published papers include:

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer, 2020, Journal of Clinical Oncology
  • Capmatinib in MET Exon 14-Mutated or MET -Amplified Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer, 2020, JAMA Oncology
  • Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study, 2023, Journal of Clinical Oncology
  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189, 2021, Annals of Oncology

Frequent co-authors include:

  • Aaron Lisberg
  • Byoung Chul Cho
  • Melissa L. Johnson
  • Enriqueta Felip
  • Rebecca S. Heist

Key publication venues for their work are:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts

Best Publications

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

    Roy S. Herbst;Paul Baas;Dong Wan Kim;Enriqueta Felip

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

    Diego Chowell;Luc G. T. Morris;Claud M. Grigg;Jeffrey K. Weber

  • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Edward B. Garon;Tudor Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash

  • Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

    Narek Shaverdian;Aaron E Lisberg;Krikor Bornazyan;Darlene Veruttipong

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee

  • Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

    Charles M. Rudin;Christine L. Hann;Edward B. Garon;Moacyr Ribeiro de Oliveira

  • Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

    Paul C. Tumeh;Matthew D. Hellmann;Omid Hamid;Katy K. Tsai

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

    Naiyer A Rizvi;Byoung Chul Cho;Niels Reinmuth;Ki Hyeong Lee

  • A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

    A. Lisberg;A. Cummings;J.W. Goldman;K. Bornazyan

  • PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

    Jyoti D. Patel;Mark A. Socinski;Edward B. Garon;Craig H. Reynolds

  • Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

    M. G. Kris;B. E. Johnson;D. J. Kwiatkowski;A. J. Iafrate

  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

    D. Rodríguez-Abreu;S.F. Powell;M.J. Hochmair;S. Gadgeel

  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

    K. Hastings;H.A. Yu;H.A. Yu;W. Wei;F. Sanchez-Vega

Frequent Co-Authors

Martin Reck
Martin Reck LungenClinic Grosshansdorf
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Steven M. Dubinett
Steven M. Dubinett University of California, Los Angeles
Roy S. Herbst
Roy S. Herbst Yale University
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
David Elashoff
David Elashoff University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean following the traditional path to an MD. There are flexible online degree options that offer specialized career opportunities and advanced credentials for healthcare professionals. For instance, registered nurses can take the next step with rn to np programs online, streamlining their journey to become nurse practitioners without putting their careers on hold.

Those interested in wellness and patient nutrition can consider earning a bachelor's in nutrition online. This credential opens doors to roles in public health, clinical settings, and community outreach.

Aspiring healthcare leaders might look to cahme-accredited online mha programs, giving graduates an edge in hospital or health system management. Meanwhile, practicing RNs seeking to advance without additional on-site requirements will find value in online rn to bsn programs no clinicals, combining flexibility and professional growth.

Each pathway supports a vital role in the evolving healthcare system, empowering students to pursue meaningful careers online.

Best Scientists Citing Edward B. Garon

Trending Scientists